Pomerantz LLP is investigating Celcuity Inc. for possible securities fraud following the company's announcement of a delayed commercial launch for its FDA-approved breast cancer drug Revtorpyk. The launch delay to late Q3 2026 was later than analysts expected, causing Celcuity's stock to fall 17.6% on July 15, 2026. The investigation focuses on whether Celcuity and its executives engaged in unlawful business practices related to this delay. Investors affected are advised to contact Pomerantz LLP for potential class action participation.
Toast CEO Aman Narang sold 138,000 shares of the company, raising $4.9 million. This sale comes as Toast's stock price has fallen 24%, signaling potential concerns or profit-taking by insiders. The move may impact investor sentiment and raise questio...
Amazon's stock surged 14% following a better-than-expected earnings report, significantly increasing Jeff Bezos' net worth by $25 billion. The strong financial performance highlights Amazon's continued growth and market strength. Investors are now ev...
Palantir's stock rose about 10% following its Q2 earnings report showing revenue of $1.94 billion, a 92.8% increase year-over-year, surpassing analyst expectations of $1.81 billion. Earnings per share came in at $0.41, beating forecasts of $0.34. Ban...
Sui (SUI) has fallen about 68% from its late 2025 high of $2.10 to around $0.69, showing signs of temporary support near $0.65. The key resistance zone between $0.72 and $0.75 must be broken for a bullish reversal, potentially pushing the price to $0...
Spot Bitcoin ETFs experienced inflows totaling $853.54 million in the past week, marking the best weekly performance since April. BlackRock's IBIT led with $693.5 million, followed by Fidelity's FBTC with $116.5 million. Despite a recent hack causing...
